孟鲁司特与变应性肉芽肿血管炎之间的相关性述评

Evaluation of relationship between montelukast and Churg-Strauss syndrome

孟鲁司特是1998年初问世的一种新型预防和治疗慢性支气管哮喘（哮喘）的药物，它是特异性阻断白三烯D4（lukotriene D4，LTD4）与半胱氨酰白三烯1受体结合的高亲和性拮抗剂（LRA）。其副作用一般来说都很轻微，但现在不断有一些哮喘患者在服用孟鲁司特后出现了变应性肉芽肿血管炎（Churg-Strauss syndrome，CSS）的表现，并进一步得到确定诊断。孟鲁司特的使用与CSS的发生究竟有无相关性，本文将就此问题综合发表文献进行述评，以期引起临床医生的重视。

In early 1998s, a kind of selective competitive antagonist of cysteinyl leukotriene D4 receptor-1,montelukast, became available, and soon was applied to prevention and treatment of chronic bronchial asthma（asthma）. Its side effects are mild overall, however, recently, there are more and more case reports have described the occurrence of Churg Strauss Syndrome （CSS） in the patients treated with montelukast. Are there any relationship between the use of montelukast and the occurrence of CSS？ According to the literature, this review is trying to figure out this point, and emphasize the clinicians should pay much attention to this phenomenon.